Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emergent BioSolutions

5.62
-0.1500-2.60%
Post-market: 5.50-0.1200-2.14%19:46 EDT
Volume:1.41M
Turnover:7.89M
Market Cap:304.52M
PE:-1.56
High:5.79
Open:5.56
Low:5.46
Close:5.77
Loading ...

Emergent BioSolutions gains exclusive commercial rights to KLOXXADO

TIPRANKS
·
14 Jan

Emergent BioSolutions: Hikma Will Continue to Manufacture Kloxxado Nasal Spray 8 Mg to Maintain Distribution and Availability

THOMSON REUTERS
·
14 Jan

Emergent BioSolutions Gains Exclusive Commercial Rights to Kloxxado® (Naloxone Hci) Nasal Spray From Hikma Pharmaceuticals

THOMSON REUTERS
·
14 Jan

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

GlobeNewswire
·
14 Jan

Emergent Gets Contract Option With BARDA for Ebola Treatment

MT Newswires Live
·
14 Jan

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration With Barda on Ebanga™ (Ansuvimab-Zykl) Treatment for Ebola

THOMSON REUTERS
·
13 Jan

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

GlobeNewswire
·
13 Jan

Emergent Biosolutions Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

Emergent BioSolutions: Strong Buy Rating Driven by Government Contracts and Growth in Medical Countermeasures

TIPRANKS
·
10 Jan

Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365%

Simply Wall St.
·
09 Jan

Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military

MT Newswires Live
·
09 Jan

BRIEF-Emergent Biosolutions Announces Exercise Of $20 Million Option To Supply U.S. Department Of Defense With Biothrax

Reuters
·
08 Jan

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GlobeNewswire
·
08 Jan

Emergent BioSolutions exercises $20M option to supply DoD with BioThrax

TIPRANKS
·
08 Jan

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense With Biothrax® (Anthrax Vaccine Adsorbed)

THOMSON REUTERS
·
08 Jan

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

GlobeNewswire
·
08 Jan